Company intelligence / Profile preview

Vazyme

Nanjing, Jiangsu, Chinavazymebiotech.com ↗

Ownership: Private
Employees: ~3000
Development stage: Commercial

Overview

Vazyme has developed over 200 recombinant enzymes and more than 1,000 high-performance materials with over 1,000 end products. The company’s diagnostic reagents are used globally in clinical laboratories for various indications. No specific clinical trial results are reported as the focus is on research tools and diagnostics rather than therapeutics.

Therapeutic areas: Men's HealthPulmonologyImmunologyOtherGastroenterologyCardiovascularNephrology
Modalities: Recombinant proteinMonoclonal antibodyAntigenEnzyme (Biologic)Diagnostic reagent
Industry: Protein Biomarker Diagnostics

Beyond the preview

Go deeper on Vazyme.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vazyme.

Explore the full profile